AGC Biologics is advancing modular single-use bioreactor systems that enable a scale-out manufacturing approach to expand production capacity while maintaining consistent conditions.
Instead of increasing vessel size as in traditional scale-up, scale-out uses multiple identical bioreactors operating in parallel to avoid changes in cell environment and performance. AGC Biologics’ platform uses 2,000 L units that can be combined to reach up to 12,000 L, allowing developers to adjust output, reduce risk tied to uncertain demand, and streamline development and validation processes. “This streamlines the flow of material and helps our partners manage resource expenditure along the development path,” said Anders Cai Holm Hansen, Principal Scientist, Customer Solution Design at AGC Biologics.
This approach supports the region’s biomanufacturing ecosystem by enabling flexible production strategies that align capacity with evolving development needs.